A thorough QT/QTc study is a specifically designed clinical trial to assess whether a drug affects cardiac repolarization by prolonging the QT or heart-rate-corrected QTc interval. The English term is Thorough QT/QTc Study. It establishes, early in the development program, a basis for how intensively ECG data need to be collected in later studies.
Research Question and Clinical Design
The ICH E14 guideline classifies the thorough QT/QTc study as an investigation intended to detect a threshold for a pharmacological effect on repolarization. It is not designed to determine whether a drug is proarrhythmic. It is typically conducted in healthy volunteers and is not designed as the very first clinical study, since tolerability and pharmacokinetics should already be known for its design.
An appropriately controlled design includes measures against bias, in particular randomization, suitable blinding, and a concurrent placebo control. Parallel-group and crossover designs may both be appropriate. The choice depends, among other things, on half-life, carry-over risk, active metabolites, and the number of doses being compared. Repeated ECG recordings help capture natural variability due to activity, body position, circadian rhythm, and food intake.
Interpreting a Negative Result
According to ICH E14, a thorough QT/QTc study is considered negative if the upper bound of the one-sided 95% confidence interval for the largest time-matched mean effect on QTc excludes 10 milliseconds. This definition is intended to provide reasonable assurance that the mean effect of the investigational drug does not exceed approximately 5 milliseconds. Outliers must also be evaluated separately as part of the assessment.
The study should characterize the relationship between dose, concentration, and time course of effect. For this reason, exposures above the expected maximum therapeutic exposure are investigated where safety and tolerability allow. ECG time points should be aligned with the pharmacokinetic profile, particularly around Cmax, although the highest serum level does not necessarily coincide with the strongest QT effect.
Distinction from the Nonclinical QT Testing Strategy
The thorough QT/QTc study is a clinical investigation conducted in humans. Its nonclinical counterpart is the testing strategy under ICH S7B for evaluating delayed ventricular repolarization. S7B comprises an in vitro IKr assay and an in vivo QT assay as complementary approaches, integrating these with additional information into an overall risk assessment.
The two levels address related but not identical questions. Nonclinical data can provide an early cardiac warning signal and shape clinical planning. The E14 result, in turn, determines whether later clinical development can generally rely on standard-of-care ECG monitoring or requires an expanded ECG safety evaluation. ICH E14 also notes rare cases in which a negative clinical result alongside strongly positive nonclinical data requires further evaluation.
An appropriate heart-rate correction is required for QTc evaluation, because the measured QT interval is inversely related to heart rate. ICH E14 notes that several correction formulas are used. ECG collection must therefore be planned so that individual variability and the timing relative to dosing are not misinterpreted as a drug effect.
A positive finding does not equate to demonstrating torsade de pointes or any other arrhythmia. However, it typically triggers an expanded ECG safety evaluation in further development. The clinical conclusion links the observed QTc effect with exposure, concomitant medication, electrolyte status, patient risk factors, and the results under ICH S7B.
The positive control should be administered concurrently so that it demonstrates the assay sensitivity of the specific study itself. If it is omitted, ICH E14 expects a justification along with alternative methods for establishing assay sensitivity; reference to earlier studies conducted under different conditions is not automatically sufficient.
Relevance for clinical trials
A TQT study requires a precise plan for ECG collection, time-matching with samples for concentration measurement, evaluation, and data quality. The selection of a high exposure level must be justified in advance based on PK, interaction, and tolerability data. A positive control or other justification of assay sensitivity ensures that a clinically meaningful difference could actually have been detected.
Full-service CROs such as Mediconomics support the design of this type of study through ECG operationalization, PK sampling time windows, coordination of centralized ECG analysis, and planning of the statistical evaluation. Clinical pharmacology, data management, and medical monitoring can thus connect the QT risk assessment with subsequent development decisions.
Frequently Asked Questions (FAQ)
When is a thorough QT/QTc study considered negative?
When the upper bound of the one-sided 95% confidence interval for the largest time-matched mean QTc effect excludes 10 milliseconds.
Why is a positive control used?
It can demonstrate that the study design is capable of detecting an effect of the magnitude of the regulatory threshold of interest.
Does a negative TQT result replace all later ECG monitoring?
A complete exemption from later ECG monitoring does not follow from this. It generally allows ECG collection according to standard therapeutic practice; the specific requirements continue to depend on the drug and the remaining data.
Regulatory References
- ICH E14, Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential – defines the design and interpretation of the thorough QT/QTc study.
- ICH S7B, The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization – describes the complementary nonclinical testing strategy.
- ICH S7A, Safety Pharmacology Studies for Human Pharmaceuticals – provides the general framework for safety pharmacology.